Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter study
Martin Nicol, Damien Logeart(Inserm), Stéphanie Harel(Hôpital Saint-Louis), Alyssa Faradji(Université Paris Cité), Bertrand Arnulf(Université Paris Cité), Michele Emdin(Scuola Superiore Sant'Anna), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Giuseppe Vergaro(Scuola Superiore Sant'Anna), Théo Pezel(Délégation Paris 5), David Lavergne, Alexis Talbot(Gladstone Institutes), Mathilde Baudet(Hôpital Lariboisière), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Cassiel Kitzinger(Université Paris Cité), V. Bousson(Université Paris Cité), Alberto Aimo(Scuola Superiore Sant'Anna), Laurent Macron(Clinique Hartmann)
Cited by 3
Related Papers
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-Year Follow-Up Outcomes and Differences Across Regions
|European Journal of Heart Failure|2016|781
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
|New England Journal of Medicine|2007|520